Skip to main content
NTRA logo

Natera, Inc. (NTRA) Stock: Price, Forecast & Analyst Target

Natera, Inc. (NTRA) — MoonshotScore 36/100 (Weak band), calculated Nov 18, 2026. Price $289.50 (+0.71%), as of the Nov 18, 2026 trading session; market cap $42.0B.

Educational signal · not a buy or sell recommendation · How to read this

$289.50 +$2.03 (+0.71%) Market Cap $42.0B

Natera, Inc. · NTRA · NASDAQ · Healthcare · Medical - Diagnostics & Research

Research dated 2026-09-12: Natera sells molecular tests used in reproductive health, cancer surveillance, and transplant monitoring, with product testing rather than licensing providing nearly all revenue. Rapid product-revenue expansion is now producing operating cash, yet accounting losses persist as research and commercial spending climbs; durable operating leverage remains the unresolved test.

Price as of Nov 18, 2026

Key Statistics

36 of 100

MoonshotScore v2 · Natera (NTRA)

Weak
Business Quality Solid (77)
Financial Safety Strained (26)
Valuation Rich (35)
Growth Durability Growing (74)
Momentum Surging (83)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 3 of the last 8 reports
  • Altman Z 28.32 · Piotroski F 2
  • ROE -10.6% · ROA -6.8% · current ratio 2.81

Holding back: balance-sheet strain

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for NTRA (57 recorded, newest six shown)
RecordedScoreBand
38Weak
37Weak
37Weak
37Weak
36Weak
36Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$289.50
Change on the day+0.71%
52-week range$181.00–$437.41
Market capitalisation$42.0B—
Shares traded on the day1.96M
Beta (volatility vs the S&P 500)1.52

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $182, high $414, latest $290. $414 $182 high $414 Oct 17, 2025 Nov 18, 2026 · $290 $182Oct 17, 2025$199Oct 31, 2025$204Nov 14, 2025$239Nov 28, 2025$232Dec 12, 2025$234Dec 26, 2025$234Jan 9, 2026$242Jan 23, 2026$203Feb 6, 2026$212Feb 20, 2026$198Mar 6, 2026$195Mar 20, 2026$208Apr 2, 2026$208Apr 17, 2026$207May 1, 2026$186May 15, 2026$223May 29, 2026$212Jun 12, 2026$262Jun 26, 2026$270Jul 10, 2026$262Jul 24, 2026$322Aug 7, 2026$332Aug 21, 2026$328Sep 4, 2026$369Sep 18, 2026$410Oct 2, 2026$393Oct 16, 2026$414Oct 30, 2026$319Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Natera (NTRA): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Weak
Growth Durability Moderate
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Natera (NTRA), and what does it report?

Short answer · as of

Natera is a testing-services business, not an instrument vendor or drug developer. Panorama and Horizon address reproductive decisions, Signatera analyzes circulating tumor DNA in oncology, and Prospera monitors organ rejection.

Reported revenue overwhelmingly reflects product activity, while licensing and other revenue is small. Constellation extends the model by giving laboratory clients access to proprietary algorithms and bioinformatics so they can validate and launch tests themselves; distribution combines direct sales with laboratory and distribution partners.

2 · Latest results

What do the latest results show for Natera (NTRA)?

Revenue advanced throughout the displayed quarterly series and reached a new series high in the latest period. Gross profit rose with it, while operating and net losses narrowed from the preceding period but remained material. Research spending increased again as selling, general and administrative expense was roughly steady.

Reported revenue exceeded the contemporaneous estimate in every earnings observation shown, yet the income statement still records losses in most periods. Positive operating cash flow shows that growth is translating into cash from operations, although the latest capital spending absorbed more cash than operations produced.

Management’s forward statement concerns a planned commercial launch contingent on final pricing and reimbursement determination. That is a future commercialization milestone, not an explanation for the latest revenue increase.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$592M-$88M-$0.64 (diluted)
Q4 FY2025$665M$47M—
Q1 FY2026$697M-$85M-$0.60 (diluted)
Q2 FY2026$753M-$67M-$0.47 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Natera (NTRA)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and short-term investments exceed debt by a wide margin and also exceed total liabilities, while the cash balance has risen across the displayed history. Operating cash flow was positive in every shown quarter.

That protection should not be confused with mature profitability. Trailing margins remain negative, the latest period still carried operating and net losses, and research spending is climbing; capital spending also exceeded operating cash inflow in the latest quarter. If test revenue slows while those costs stay elevated, the route from gross profit to durable free cash flow becomes harder.

Valuation magnifies execution risk: sales and book multiples are elevated, while free cash flow yield is thin and net cash is modest beside market value. The balance sheet can absorb setbacks, but it cannot by itself justify the equity value.

Data-derived red flags

  • Negative return on equity (-10.6%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Natera (NTRA)?

Short answer · as of

Current published price targets run low $245.00 · high $500.00 · consensus $393.16 · median $407.50 against a quoted price of $289.50 (as of Nov 18, 2026).

The next earnings expectation calls for revenue below the latest reported level even as the expected loss per share narrows. Watch whether product-test revenue holds its trajectory, gross profit grows faster than research and commercial costs, and operating cash flow again exceeds capital spending.

Commercially, the named checkpoint is final pricing and reimbursement determination for the planned launch. Confirmation would be launch progress paired with product revenue and cash conversion; slippage or weak economics would leave the current spending ramp carrying more of the burden.

Longer-range consensus assumes continued revenue expansion and eventual positive earnings, while current multiples already reflect substantial expectations. The useful comparison is not merely against consensus revenue; it is whether loss contraction becomes repeatable rather than appearing intermittently.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Natera compare with its peers?

Short answer

Natera's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Natera differs through the combination of reproductive testing, circulating-tumor-DNA surveillance, transplant monitoring, and a cloud platform that lets laboratory clients use its algorithms. This is not a licensing-led genomics model: reported revenue is overwhelmingly product revenue, so adoption and utilization of Natera’s tests matter far more than software fees.

That mix provides several routes to clinical demand without changing the core engine: molecular tests distributed directly and through laboratory partners. Breadth does not remove the need for product testing to fund a large research and sales base.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
IDEXX Laboratories, Inc. (IDXX) Same industry, near in market value$698.47 Nov 18, 2026$55.0B96 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Named competitor$82.52 Nov 18, 2026$30.8B93 5-pillar Nov 18, 2026
Mettler-Toledo International Inc. (MTD) Same industry, near in market value$1737.26 Nov 18, 2026$34.6B93 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Same industry, near in market value$646.87 Nov 18, 2026$18.1B92 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Named competitor$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Same industry, near in market value$177.33 Nov 18, 2026$50.0B83 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Named competitor$29.81 Nov 18, 2026$29.1B78 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Same industry, near in market value$259.52 Nov 18, 2026$28.6B74 5-pillar Nov 18, 2026
IQVIA Holdings Inc. (IQV) Named competitor$257.84 Nov 18, 2026$42.5B71 5-pillar Nov 18, 2026
Labcorp Holdings Inc. (LH) Same industry, near in market value$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026
Revvity, Inc. (RVTY) Same industry, near in market value$152.43 Nov 18, 2026$17.0B71 5-pillar Nov 18, 2026
Charles River Laboratories International, Inc. (CRL) Same industry, near in market value$333.25 Nov 18, 2026$16.0B70 5-pillar Nov 18, 2026
Natera (NTRA) — this page$289.50$42.0B36

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$245.00 – $500.00
Consensus target
$393.16
Median target
$407.50

Consensus record · Captured .

Measured against a quoted price of $289.50 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
60
Identified insiders
7
Purchases
0
Sales
60
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NTRA in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 202629.22%$1.31BTrimmed −0.8% shares
CoatuePhilippe LaffontQ3 20261.84%$1.00BTrimmed −3.0% shares
ARK InvestCathie WoodQ3 20261.30%$225.73MTrimmed −20.7% shares
Bridgewater AssociatesFounded by Ray DalioQ3 20260.05%$11.01MAdded +334.2% shares
Viking GlobalAndreas HalvorsenQ3 20260%$0Sold out (was $106.05M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Natera (NTRA)?

Read these with our analysis →

Natera Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

How does Signatera differ from Panorama in Natera’s portfolio?

Panorama screens a pregnancy for fetal chromosomal abnormalities from maternal blood, while Signatera uses circulating tumor DNA in cancer-related testing. They address distinct clinical settings but feed the same product-led testing model.

Why does Constellation matter when Natera is a product-testing company?

Constellation lets laboratory clients use Natera’s algorithms and bioinformatics to validate and launch their own tests. It broadens access to the company’s technology, although licensing and other revenue remains small beside product revenue.

Can Natera keep funding Signatera and reproductive testing while reporting losses?

Net cash and positive operating cash flow across the displayed quarters provide meaningful funding capacity. Rising research expense, negative margins, and a latest period in which capital spending exceeded operating inflow make cash conversion the constraint to watch.

What stands between Natera and its planned commercial launch?

Final pricing and reimbursement determination is the stated condition, and management described that work as on track. Subsequent product revenue and cash conversion would show whether the launch is economically meaningful.

What is the NTRA stock price today?

The last price recorded for Natera, Inc. (NTRA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the NTRA price target?

The analyst consensus price target for Natera, Inc. (NTRA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Natera (NTRA), and what does it report?: Business description; Revenue by segment
  • 2. What do the latest results show for Natera (NTRA)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Natera (NTRA)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Cash against market value
  • 4. What should you watch next at Natera (NTRA)?: Next earnings report; Quarterly income statement (USD thousands); Revenue by segment; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts; Analyst revenue and earnings estimates (average); Trailing twelve-month ratio set; Reported versus estimated, last 8 quarters
  • 5. How does Natera compare with its peers?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: How does Signatera differ from Panorama in Natera’s portfolio?: Business description; Revenue by segment
  • FAQ: Why does Constellation matter when Natera is a product-testing company?: Business description; Revenue by segment
  • FAQ: Can Natera keep funding Signatera and reproductive testing while reporting losses?: Cash, investments and debt; Cash against market value; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: What stands between Natera and its planned commercial launch?: Management outlook — dated call excerpts; Revenue by segment; Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold NTRA

Funds in our ETF coverage that list NTRA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Global X - Genomics & Biotechnology ETF (GNOM)3.91%
WisdomTree BioRevolution Fund (WDNA)2.44%
iShares Morningstar Small-Cap Growth ETF (JKK)0.95%